Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.72 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614998 | 1.00 | AR (0.72) | ARSRD5A2KCNH2 | |
| SCHEMBL14013760 | 0.90 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5247649 | 0.90 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5116733 | 0.90 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL5874196 | 0.90 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL13403347 | 0.90 | AR (0.74) | ARSRD5A2KCNH2 | |
| SCHEMBL11005803 | 0.88 | AR (0.68) | ARSRD5A2KCNH2 | |
| SCHEMBL11005799 | 0.88 | AR (0.68) | ARSRD5A2KCNH2 | |
| SCHEMBL14493967 | 0.87 | AR (0.70) | ARSRD5A2KCNH2 | |
| SCHEMBL13465160 | 0.87 | AR (0.70) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-6268376-B1 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
| EP-0285382-B1 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0285383-B1 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO INC (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4760071-A | Enzyme inhibitor | MERCK & CO., INC. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0155096-A2 | 17 Beta-Substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1985-09-18 | — | — | EP | disclosed |